MX2022006366A - Terapia de combinacion que implica compuestos de diarilo macrociclico. - Google Patents

Terapia de combinacion que implica compuestos de diarilo macrociclico.

Info

Publication number
MX2022006366A
MX2022006366A MX2022006366A MX2022006366A MX2022006366A MX 2022006366 A MX2022006366 A MX 2022006366A MX 2022006366 A MX2022006366 A MX 2022006366A MX 2022006366 A MX2022006366 A MX 2022006366A MX 2022006366 A MX2022006366 A MX 2022006366A
Authority
MX
Mexico
Prior art keywords
combination therapy
macrocyclic compounds
therapy involving
diaryl
diaryl macrocyclic
Prior art date
Application number
MX2022006366A
Other languages
English (en)
Inventor
Wei Deng
Dayong Zhai
Jingrong J Cui
Laura Rodon
Brion W Murray
Nathan V Lee
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2022006366A publication Critical patent/MX2022006366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere a métodos y composiciones para tratar el cáncer con un diarilo macrocíclico en combinación con un inhibidor de MAPK/ERK cinasa-1 y -2 (MEK1 y MEK2; MAP2K1 y MAP2K2), tal como trametinib.
MX2022006366A 2019-11-27 2020-11-25 Terapia de combinacion que implica compuestos de diarilo macrociclico. MX2022006366A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941033P 2019-11-27 2019-11-27
US201962941031P 2019-11-27 2019-11-27
US202062992573P 2020-03-20 2020-03-20
PCT/US2020/062374 WO2021108672A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
MX2022006366A true MX2022006366A (es) 2022-06-22

Family

ID=75971599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006366A MX2022006366A (es) 2019-11-27 2020-11-25 Terapia de combinacion que implica compuestos de diarilo macrociclico.

Country Status (12)

Country Link
US (2) US11666574B2 (es)
EP (1) EP4065395A4 (es)
JP (1) JP2023504046A (es)
KR (1) KR20220134522A (es)
CN (1) CN114867622A (es)
AU (1) AU2020391220A1 (es)
BR (1) BR112022010277A2 (es)
CA (1) CA3163095A1 (es)
IL (1) IL293208A (es)
MX (1) MX2022006366A (es)
TW (1) TW202133856A (es)
WO (1) WO2021108672A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654145B2 (en) * 2019-11-27 2023-05-23 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
IL297650A (en) * 2020-04-27 2022-12-01 Verastem Inc Methods for treating abnormal cell growth
CA3229057A1 (en) * 2021-08-30 2023-03-09 Ravid STRAUSSMAN Combination therapy with a mek inhibitor and a src inhibitor for the treatment of colorectal cancer
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
US20230293463A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of cutaneous neurofibromas with Mirdametinib
WO2023178284A1 (en) * 2022-03-17 2023-09-21 St. Jude Children’S Research Hospital Treatment of low-grade glioma with mirdametinib
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
SG10202000191YA (en) 2014-01-24 2020-03-30 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
ES2945387T3 (es) 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP6871903B2 (ja) * 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
US10294242B2 (en) 2015-07-06 2019-05-21 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
AU2016296878B2 (en) 2015-07-21 2020-12-17 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CN108697661A (zh) * 2015-12-18 2018-10-23 亚尼塔公司 用于治疗癌症的组合
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法

Also Published As

Publication number Publication date
US20230398119A1 (en) 2023-12-14
EP4065395A1 (en) 2022-10-05
KR20220134522A (ko) 2022-10-05
BR112022010277A2 (pt) 2022-10-11
JP2023504046A (ja) 2023-02-01
US11666574B2 (en) 2023-06-06
US20210154198A1 (en) 2021-05-27
WO2021108672A1 (en) 2021-06-03
CN114867622A (zh) 2022-08-05
EP4065395A4 (en) 2024-02-14
IL293208A (en) 2022-07-01
AU2020391220A1 (en) 2022-06-30
CA3163095A1 (en) 2021-06-03
TW202133856A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12019501328A1 (en) 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
HK1130438A1 (en) Using pi3k and mek modulators in treatments of cancer
EP4012415A3 (en) Methods and compositions related to toxicity associated with cell therapy
ECSP088423A (es) Combinaciones antineoplasicas con inhibidor de objetivo de rapamicina en mamiferos, herceptina, y/o hki-272
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2022001933A (es) Inhibidores de enzimas.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2022000811A (es) Inhibidores de enzimas.
ZA202107139B (en) Methods and compositions for treating cancer
AR093112A1 (es) Metodos para determinar indice reactivo de polvo de horno de cemento, composiciones asociadas y metodos de uso
WO2020055906A8 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)